Abstract: The present invention relates to compounds of formula (I) for stabilizing the tetrameric form of transthyretin, compounds for use in the treatment or prevention of amyloidosis, and agents and medicaments comprising such compounds. wherein X, Y, R1, R2, R3, R4, m, n, p, q, and the linker are as defined herein.
Type:
Grant
Filed:
March 22, 2010
Date of Patent:
August 7, 2012
Assignee:
Pentraxin Therapeutics Ltd.
Inventors:
Mark Brian Pepys, Steven Victor Ley, Angus John Morrison, Vittorio Bellotti, Simon Kolstoe, Martin Smith
Abstract: The invention describes the use of an antibody specific for serum amyloid P component, for the treatment or prophylaxis of amyloidosis, and the use of a compound which depletes serum amyloid P component from the circulation in combination with an antibody specific for serum amyloid P component.
Abstract: Agent for the depletion of an unwanted protein population from the plasma of a subject, which agent comprises a plurality of ligands covalently co-linked so as to form a complex with a plurality of the proteins in the presence thereof, wherein at least two of the ligands are the same or different and are capable of being bound by ligand binding sites present on the proteins, wherein the agent is a non-proteinaceous agent other than a D-proline of the formula wherein R is the group R1 is hydrogen or halogen; X is —(CH2)n—; —CH(R2)(CH2)n—; —CH2O(CH2)n—; —CH2NH—; benzyl, —C(R2)?CH—; —CH2CH(OH)—; or thiazol-2,5-diyl; Y is —S—S—; —(CH2)n—; —O—; —NH—; —N(R2)—; —CH?CH—; —NHC(O)NH—;—N(R2)C(O)N(R2)—; —N[CH2C6H3(OCH3)2]—; —N(CH2C6H5)—; —N(CH2C6H5)C(O)N(CH2C6H5)—; —N(alkoxyalkyl)-; N(cycloalkyl-methyl)-; 2,6-pyridyl; 2,5-furanyl; 2,5-thienyl; 1,2-cyclohexyl; 1,3-cyclohexyl; 1,4-cyclohexyl; 1,2-naphthyl; 1,4-naphthyl; 1,5-naphthyl; 1,6-naphthyl; biphenylen; or 1,2-phenylen, 1,3-phenylen and 1,4-phenylen, wher